This clinical trial explores a potential new approach to managing Obstructive Sleep Apnea (OSA). The research focuses on an investigational oral medication designed to address two key aspects of the condition simultaneously: reducing the physical blockage in the upper airway during sleep and lowering the high blood pressure that can often occur at night (nocturnal hypertension) as a consequence of OSA. The key objective is to validate if this single medication can provide these dual benefits.